0
Clinical Investigations: CANCER |

Beliefs Among Pulmonologists and Thoracic Surgeons in the Therapeutic Approach to Non-small Cell Lung Cancer*

Anneke T. Schroen, MD, MPH; Frank C. Detterbeck, MD, FCCP; Robert Crawford, MBA; M. Patricia Rivera, MD, FCCP; Mark A. Socinski, MD
Author and Funding Information

*From the Robert Wood Johnson Clinical Scholars Program (Dr. Schroen) and the Multidisciplinary Thoracic Oncology Program (Drs. Detterbeck, Rivera, and Socinski and Mr. Crawford), University of North Carolina, Chapel Hill, NC.

Correspondence to: Mark A Socinski, MD, Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, CB No. 7305, 3006 Old Clinic Building 202, Chapel Hill, NC 27599-7305; e-mail: socinski@med.unc.edu



Chest. 2000;118(1):129-137. doi:10.1378/chest.118.1.129
Text Size: A A A
Published online

Study objectives: The physicians who initially evaluate patients with non-small cell lung cancer (NSCLC) strongly impact the course of therapy. Their beliefs in treatment and prognosis may contribute to practices of variable quality and appropriateness. We sought to better describe beliefs among pulmonologists and thoracic surgeons who were selected for guiding early therapy and referrals in patients with NSCLC.

Design: Mail questionnaire focusing on survival estimates, treatment perceptions, and referral patterns.

Participants:Twelve hundred pulmonologists and 800 thoracic surgeons who were clinically active members of the American College of Chest Physicians.

Measurements and results: Response rates of 50% for pulmonologists and 52% for thoracic surgeons were obtained after two mailings. Five-year survival estimates for patients with resected stage I NSCLC revealed that 30% of respondents overestimated survival rates and 18% underestimated survival rates. The underestimation of survival rate was found among more respondents who are practicing pulmonology than thoracic surgery (22% vs 0.10%, respectively), who were trained before 1980 than after 1980 (29% vs 0.10%, respectively), and who were seeing < 10 lung cancer patients annually than those who were seeing > 25 (31% vs 0.14%, respectively). Beliefs in the survival benefit of adjuvant chemotherapy or of radiation in stage I-IIIA disease divided respondents within both specialties. Chemotherapy plus radiation vs radiation alone in unresectable stage IIIA-B NSCLC was viewed as benefiting survival less often by physicians seeing < 10 lung cancer patients annually rather than > 25 (57% vs 0.77%, respectively) and by physicians underestimating rather than correctly estimating survival in early-stage disease (58% vs 0.72%, respectively). Chemotherapy was believed to confer survival benefits in patients with stage IV disease by one third of respondents.

Conclusions: Certain physician characteristics, particularly the length of time since training and NSCLC patient volume, are associated with beliefs not conclusively supported in the medical literature or with opinions inconsistent within and between specialties.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543